Athersys

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. The Company is engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of the proprietary technologies, Athersys has established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.

Revenue(FY, 2017)

$3.7 M

Market capitalization(2018-04-18)

$226.3 M

Patent Applications (FY, 2016)

170

Type

Public

Cleveland, US

Founded

1995

Size (employees)

60 (est)

Website

athersys.com

Athersys was founded in 1995 and is headquartered in Cleveland, US

Report incorrect company information

Key People/Management at Athersys

Gil Van Bokkelen

Chairman & CEO

William Lehmann Jr

President, COO

John Harrington

Executive Vice President and Chief Scientific Officer

Laura Campbell

Controller

Manal Morsy

Vice President, Global Regulatory Affairs

Report incorrect company information

Athersys Office Locations

Athersys has offices in Canton and Cleveland

Cleveland, US (HQ)

3201 Carnegie Ave

Canton, US

250 Royall St

Show all (2)

Report incorrect company information

Athersys Financials and Metrics

Athersys Financials

Athersys's revenue was reported to be $3.71 m in FY, 2017

Summary

USD
Revenue (FY, 2017)	3.7 m
EBIT (FY, 2017)	(33.3 m)
Market capitalization (18-Apr-2018)	226.3 m
Cash (31-Dec-2017)	29.3 m

Athersys's current market capitalization is $226.3 m.

Source: SEC Filings

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Revenue	2.4 m	1.6 m	11.9 m	17.3 m	3.7 m
Revenue growth, %		(33%)	636%	45%
General and administrative expense					8.5 m
R&D expense					27.8 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Revenue	621 k	707 k	388 k	293 k	731 k	216 k	396 k	15.5 m	595 k	311 k	1.5 m	669 k
General and administrative expense	1.5 m	1.8 m	1.8 m	1.7 m	1.9 m	1.9 m	1.9 m	2 m	2 m	1.8 m	2.1 m	2.2 m
R&D expense	4.7 m	6.2 m	5.8 m	5.8 m	5.7 m	5.3 m	5.1 m	6.7 m	5.8 m	5.3 m	5.6 m	4.6 m
Operating expense total	6.2 m	8.1 m	7.7 m	7.6 m	7.6 m	7.3 m	7.1 m	8.7 m	7.9 m	7.2 m	7.9 m	7 m

show all

Source: SEC Filings

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	31.9 m	26.1 m	23 m	14.8 m	29.3 m
Accounts Receivable	520 k	694 k	361 k	598 k	739 k
Current Assets	32.9 m	27.2 m	23.8 m	16.3 m	31.2 m
Total Assets	34.2 m	28.7 m	25.1 m	19.1 m	33.6 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Cash	17.8 m	45 m	38.8 m	32.4 m	35.5 m	32.3 m	28.5 m	30.4 m	13.8 m	8.3 m	31.9 m	28.6 m
Accounts Receivable	453 k	894 k	715 k	665 k						298 k	1.8 m
Current Assets	18.6 m	46.2 m	39.8 m	33.4 m	38.7 m	35.1 m	29.2 m	31.5 m	25.7 m	20.5 m	34.9 m	30.1 m
Total Assets	19.9 m	47.6 m	41.1 m	34.8 m	40.2 m	36.5 m	30.6 m	33 m	27.9 m	23.3 m	37.6 m	32.7 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(30.7 m)	(22.1 m)	(16.4 m)	(15.3 m)	(32.2 m)
Depreciation and Amortization	346 k	360 k	267 k	382 k	684 k
Accounts Payable	(196 k)	335 k	(296 k)	2.4 m	1.5 m
Cash From Operating Activities	(22.8 m)	(25.8 m)	(13.8 m)	(10.9 m)	(24 m)

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Net Income	(5.6 m)
Depreciation and Amortization	86 k	89 k	93 k	91 k	70 k	65 k	66 k	68 k	67 k	114 k	164 k
Accounts Payable			2.8 m	2.9 m	2.7 m	2.3 m	2.6 m	3.3 m	4.2 m	3.6 m	6.6 m